Submit your nominations for the Verl Zanders Emerging Business of the Year! Nominate your choice for an emerging company that is leading innovation in Metro-Maryland.
The Tech Council of Maryland is pleased to announce that Martin “Marty” Rosendale has been appointed as senior executive advisor. In this role, he will assist the association and board of directors in fulfilling its strategic plan objectives.
Marty is a member of the Tech Council and is CEO of Selnova LLC, an advisory firm founded to help entrepreneurs navigate critical and challenging company transitions. He is also a founding member of the managing committee that established and oversees TCM’s Venture Mentoring Service, where he and other TCM members act as mentors and provide their expertise to promising Maryland tech and life sciences companies that are preparing for an initial venture or institutional financing event.
Montgomery County Executive Ike Leggett is asking the business community to provide feedback on County services by completing an online Business Survey.
Mr. Leggett has kicked off the Excellence in Business Services initiative, continuing his efforts to make it easier for businesses to start, grow and thrive in Montgomery County. This business survey is designed to help the county identify areas of improvement in its interactions with business.
Business vitality is critical to a healthy economy that supports the quality of life we all enjoy and Montgomery County is committed to ensuring that businesses have a positive experience when interacting with the County.
Businesses also are welcome to contact the project lead directly with thoughts and feedback: Judy Stephenson judy.stephenson@montgomerycountymd.gov
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient. The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (Tβ4) over a period of time, as well as treating a patient by maintaining a desired concentration of Tβ4 in a pharmacologically effective range. The patent expiry will be in late 2031, or longer depending on any extensions available from the USPTO.
Digital health technology leader WellDoc today announced a collaboration with Human API, the fastest-growing health data platform, through which the two companies will explore the unique integration of type 2 diabetes patient health data within WellDoc’s BlueStar digital therapeutic. Human API’s data platform will provide WellDoc with real-time access to comprehensive clinical patient data from its network of 15,000+ pharmacies, health systems and laboratories. The steady flow of data is shared within a highly secure environment that ensures protection of data and patient privacy.
Gaithersburg, MD’s Altimmune has secured a sizable contract with BARDA to further develop its nasal spray anthrax vaccine candidate, building on an existing collaboration as the biotech prepares to move into clinical trials.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares of Aptevo common stock to the holders of Emergent BioSolutions common stock. As a result of the spin-off, Aptevo is now an independent public company and listed on the Nasdaq Global Select Market under the ticker symbol “APVO.”
GlaxoSmithKline and Alphabet unit Verily (formerly Google Life Sciences) made a splash yesterday when they announced the launch of Galvani Bioelectronics, a company that will build upon GSK’s three years of work to develop tiny nerve-altering devices that might one day be used instead of drugs to treat a variety of diseases. The two companies will invest up to £540 million (more than $700 million) over the next seven years, they said, employing 30 scientists at GSK’s research center in the U.K. and at Verily in South San Francisco.
Help MdBio Foundation kick off the school year with an ice cream cone and tour of MdBioLab. Tour the lab, meet the team or just eat your ice cream. Doors open 12 – 3PM.
August 31, 2016 | 12PM – 3PM | JHU MoCo Parking Lot
August 1, 2016: All Points, Maryland – Today Startup Maryland announced dates (September 10 – October 8) and the rough route for the STRT1UP Road Show, the fifth annual state-wide tour and celebration of entrepreneurship and high-growth innovation-centric startup companies.
Roche ($ROG) and Inovio Pharmaceuticals ($INO) had hoped to develop immunotherapies to treat prostate cancer and hepatitis B when they first partnered in 2013. But now that dream is officially dead as Roche has returned the second of two candidates and discontinued its partnership with Inovio.
Wednesday, September 7, 2016 – 6:00pm, CareFirst Tower, Baltimore, MD
We’re celebrating 11 years of raising awareness about sickle cell disease! Put on something RED and join us at the CareFirst Tower in Canton for an evening of good food, fun and networking with friends – plus a glorious view of the Baltimore harbor. We’re honoring Clinical Research Teams as Unsung Heroes.
Dr. Gary Gibbons, Director of NHLBI, will attend and receive a Distinguished Service Award.
We are delighted to announce Illumina Accelerator is accepting applications for its next funding cycle in San Francisco. Illumina Accelerator is the world’s first business accelerator focused on creating an innovation ecosystem for the genomics industry. It drives value for genomics startups developing breakthrough applications in therapeutics, diagnostics, agriculture, direct to consumer, synthetic biology, and beyond. Selected genomics startups will receive seed investment, business guidance, and fully operational lab space for six months in San Francisco, starting in January 2017. Applications for the fifth funding cycle are due by September 1, 2016.
Yes, Hollywood may dramatize the plight of the entrepreneur. But sometimes the best way to capture reality is through fiction. Wherever you are in your business venture, you can glean some insight from these 18 provocative and wildly entertaining films.
If immunotherapy has the cancer community riveted on the treatment side, liquid biopsies are equally exciting on the diagnostics end. And IBM is bringing its research heft to bear on the world of liquid biopsy with an intent to build a lab-on-a-chip technology that can separate particles at the nanoscale.
EU and US strengthen their collaboration on eHealth IT
In December 2010, the US Department of Health and Human Services (HHS) and the European Commission’s DG CONNECT signed a Memorandum of UnderstandingWeb Site Disclaimers (MoU) for transatlantic Cooperation on eHealth/Health IT.
In the spring of 2013, DG CONNECT and HHS published a first Roadmap of MoU actionsWeb Site Disclaimers, focusing on two priority areas (work-streams):
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
